1851 Harbor Bay Parkway
819 articles about Exelixis, Inc.
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close.
MacroGenics' Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis' Cabometyx combo improves PFS in renal cell carcinoma.
Exelixis' Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Exelixis intends to discuss the results with the U.S. FDA to determine next steps toward a potential regulatory submission.
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING technology.
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
Exelixis, Inc. announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022.
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor.
This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
Exelixis, Inc. and BioInvent International AB announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics.
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June 2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June.
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from multiple cohorts of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
Exelixis, Inc. reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May 2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2022 Healthcare Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 11, 2022 in Las Vegas.
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114.
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.